Showing session: reset
Making Science Count for Patients: CDK4/6
- Sort by:
- Browse by:
- Free
- audio + slides
- Some slides withheld
CDK 4/6 inhibitors: Preclinical, approval, and optimization
Richard S Finn
UCLA, Los Angeles, CA, United States
- Free
- audio + slides
- Some slides withheld
CDK 46/inhibitors: Beyond efficacy speaker
Ben O'Leary
Royal Marsden Hospital Inst. of Cancer Res., London, United Kingdom
- Free
- audio + slides
- Some slides withheld
CDK 4/6 inhibitors: Evolving data outside of breast cancer
Jessica Teh
Thomas Jefferson Univ., Philadelphia, PA, United States